Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial
Jun 1, 2022
LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research Safety profile is favourable and consistent with previous HMTM studies TauRx will now pursue regulatory submission and coverage for HMTM SINGAPORE, June 1, 2022 /PRNewswire/ --TauRx Pharmaceuticals Ltd, the global leader in tau-based research in Alzheimer's, today announced unblinding of initial